Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liao-Shi-Hua-Feng-Dan is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of cerebrovascular diseases, including ischemic stroke and intracerebral hemorrhage. Developed within the Liao family lineage and manufactured by Guizhou Liangji Pharmaceutical, the drug is a complex mixture of botanical and mineral ingredients designed to extinguish wind and resolve phlegm according to TCM principles. It is commonly used in the clinical management of stroke sequelae and facial paralysis in China. Recent clinical research, including registry studies led by Dongzhimen Hospital, aims to provide real-world evidence for its efficacy in improving neurological outcomes and reducing disability in stroke patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liao-Shi-Hua-Feng-Dan.